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Background

PD-L1

Results

• High efficacy of Immune Checkpoint Blockade
• Restricted to some cancers and some patients
• PD-L1 and PD-L2 are widely expressed by tumor
cells and the immunosuppressive stroma
• Blocking only PD-1 or PD-L1 does not address
the whole pathway
• Bispecific antibodies offer dual ligand blockade
• Fc region modification can enhance antibody
functionality

Objectives

BsAbs:
 targeting PD-L1 and PD-L2 and
bearing the Fc modification
promote superior ADCC activity
against target cells that express
either ligand by effector cells
expressing Fc receptors.
 mostly share the same epitope
as clinical anti-PD-L1
monospecific antibodies.
 possess higher in vivo efficacy
than a reference anti-PD-1
therapeutic antibody.

Figure 1: Modified bsAbs induce higher ADCC activation than clinical
anti-PD-L1 antibodies.

Future Directions

Figure 2: Modified bsAbs mostly share the same binding region on
PD-L1 as clinical anti-PD-L1 antibodies.

• Assess the survival benefit of
targeting PD-L1/2 for ADCC and
its combination with other
immunotherapies in vivo.
• Investigate the interactions
between the structure of human
PD-L1/2 extracellular regions
and the anti-PDL1/2 BsAbs using nuclear
measured resonance (NMR).
• Determine and compare the
binding affinity of these
interactions measured by
surface plasmon resonance.

• Compare the efficacy of Fc-modified human antiPD-L1/2 bispecific antibodies (BsAbs) and
clinical anti-PD-L1 antibodies to induce antibody
dependent cell-mediated cytotoxicity (ADCC).
• Investigate whether the human anti-PDL1/2 BsAbs have the same binding region on PDL1 or PD-L2 as clinical or commercial antibodies.
• Examine the in vivo efficacy of anti-PDL1/2 BsAbs within a cancer cell model.

Methodology
ADCC assay

Target cells Antigen/Antibody

FcyR on ADCC
effector cells

NFAT pathway

Acknowledgements

Promega Corporation

• All Curran members

Flow Competition assay

References

Flow
cytometry
Unlabeled Labeled biPDL
commercial Ab

Colon cancer model
BiPDL treatment
DO (Colon
Cancer Cells)

D6

D12

Figure 3: Modified bsAbs demonstrate higher in vivo efficacy than an
anti-PD-1 antibody
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